Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 0.5% Ivermectin Cream | Experimental |
| |
| Vehicle control | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ivermectin Cream | Drug | Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success defined as absence of live lice, was assessed in index participants, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. | Day 2 up to Day 15 post-application |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. | Day 2 up to Day 15 post-application |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Sanofi Topaz | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cactus Kids Pediatrics | Yuma | Arizona | 85364 | United States | ||
| Universal Biopharma Research, Inc |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23113480 | Derived | Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med. 2012 Nov 1;367(18):1687-93. doi: 10.1056/NEJMoa1200107. |
Not provided
Not provided
A total of 410 participants who met the inclusion and exclusion criteria were enrolled and treated.
Participants were enrolled and treated from 8 March 2010 to 9 June 2010 in 8 US clinical centers.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 0.5% Ivermectin | Participants underwent a single treatment with 0.5% ivermectin cream at home on Day 1. |
| FG001 | Vehicle Control | Participants underwent a single treatment with vehicle control cream at home on Day 1. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| vehicle control | Drug | Up to 4 ounces of vehicle control applied to the hair and scalp on day 1 |
|
| Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Severity of the adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention. | Day 1 up to Day 15 post-application. |
| Summary of the Reported Skin/Scalp Irritation Before Treatment and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp. | Day 1 up to Day 15 post-application |
| Dinuba |
| California |
| 93618 |
| United States |
| Lice Source Services, Inc. | Plantation | Florida | 33313 | United States |
| LSRN | West Palm | Florida | 33407 | United States |
| Spence Medical Research | Picayune | Mississippi | 39466 | United States |
| Hill Top Research | Miamiville | Ohio | 45147 | United States |
| McKenzie Medical Center | McKenzie | Tennessee | 38201 | United States |
| Virginia Clinical Research, Inc. | Norfolk | Virginia | 23507 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 0.5% Ivermectin | Participants underwent a single treatment with 0.5% ivermectin cream at home on Day 1. |
| BG001 | Vehicle Control | Participants underwent a single treatment with vehicle control cream at home on Day 1. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success defined as absence of live lice, was assessed in index participants, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. | Treatment success was assessed in the Intent-to-treat population. Any participant with live lice on or after Day 2 received an FDA approved head lice treatment and was classified as a treatment failure, imputed as such for remaining assessments. | Posted | Number | Percent of Participants | Day 2 up to Day 15 post-application |
|
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation. | Treatment success was assessed in the Intent-to-treat population. Any participant with live lice on or after Day 2 received an FDA approved head lice treatment and was classified as a treatment failure, imputed as such for remaining assessments. | Posted | Number | Percent of Participants | Day 2 up to Day 15 post-application |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Severity of the adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention. | Adverse events were assessed in the Intent-to-treat (Safety) population. | Posted | Number | Participants | Day 1 up to Day 15 post-application. |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Summary of the Reported Skin/Scalp Irritation Before Treatment and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp. | Skin/scalp irritation was assessed in the Intent-to-treat (Safety) population. | Posted | Number | Participants | Day 1 up to Day 15 post-application |
|
|
Adverse event data were collected from the day of application (Day 1) through Day 15 post-application.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 0.5% Ivermectin | Participants underwent a single treatment with 0.5% ivermectin cream at home on Day 1. | 0 | 210 | 0 | 210 | ||
| EG001 | Vehicle Control | Participants underwent a single treatment with vehicle control cream at home on Day 1. | 0 | 199 | 0 | 199 |
Not provided
Not provided
Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director | Sanofi Topaz | RegistryContactUs@sanofipasteur.com |
| >=65 years |
|
| Male |
|
|
|
|